Abstract: This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described herm partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described herm relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.

Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.

Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.

Abstract: This invention relates to antibodies specific for human interleukin-38 (IL-38), including isolated antibodies, or antigen-binding fragments thereof. The antibodies, or antigen-binding fragments thereof, described here partially or fully block, inhibit, or neutralize a biological activity of IL 38. Methods described here relate to inhibiting tumor growth or metastasis in an individual afflicted by tumor growth and/or metastasis.

Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.

Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Abstract: Described herein, are antibodies specific for epsin-1 (EPN1), an antigen expressed on the surface of various cancer cells. Methods for treating, ameliorating and diagnosing various types of cancers characterized by EPN1-expressing tumor cells are also disclosed.

Abstract: The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 (“PD-L1”) as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by targeting tumor-cell derived exosomes that inhibit T cell activation. Therefore, bispecific antibodies of the invention can be used in methods for treating cancers.

Abstract: This invention relates to the incorporation of one, or more, heterologous antibody epitopes into the AB, EF, or CD structural loops of the constant heavy domain 3 (“CH3 domain”) of an engineered antibody or Fc-linked therapeutic agent. The heterologous epitopes serve as “epitope tags” that are specifically detectable by epitope tag-specific detector antibodies, irrespective of the tagged agent's target specificity. Therefore, the epitope tags are useful for the rapid detection of any tagged antibody or Fc-linked agent in biological samples, including samples, which also contain endogenous antibodies.

Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Abstract: Constructs comprising pH low insertion peptide and variants thereof conjugated to monomethyl auristatins and analogs thereof are described. These constructs are useful, for example, in the treatment of solid tumors, including the treatment of breast cancer and prostate cancer, as well as other cancers such as pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, skin cancer, kidney cancer, and colon cancer. The constructs inhibit tumor cell proliferation and reduce tumor volume, particularly in a low pH tumor environment.

Abstract: Methods for generating hybrid antibodies are provided.

Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.

Abstract: Methods for generating hybrid antibodies are provided.

Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.

Abstract: Methods for treating tumors comprising cells overexpressing ErbB2 or ErbB3 are provided, and comprise inhibiting the biologic activity of one or more of ErbB2 and ErbB3 in the cells and inhibiting the expression or the biologic activity of a constituent of a signal pathway connected with ErbB2 or ErbB3 signaling.

Abstract: Compositions and methods useful for the diagnosis and treatment of cancer are provided.